News

W. Fraser Symmans, MD, discusses data on the current state of AI-driven digital pathology in HR+ breast cancer.

Dato-DXd plus durvalumab showed promising efficacy in locally advanced or metastatic triple-negative breast cancer.

Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Ultra-hypofractionted radiotherapy yielded responses in locally advanced breast cancer.

T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

A ctDNA blood test predicted metastatic risk, but not local recurrence, after bladder-sparing cancer treatment.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.

The FDA has approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Shubham Pant, MD, MBBS, discusses the importance of early biomarker testing in mCRC to guide targeted therapy selection and ensure full clinical benefit.

Data from KEYNOTE-B96 supported the first FDA approval of an immunotherapy regimen in PD-L1–positive platinum-resistant, recurrent ovarian cancer.

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

Tycel Phillips, MD, discusses key questions on optimal BTK inhibitor strategies in mantle cell lymphoma.

Allo-HSCT did not improve survival outcomes in patients with lower-risk myelodysplastic syndrome who had some higher-risk features.

Treatment with subcutaneous amivantamab plus pembrolizumab was deemed effective and safe in patients with recurrent or metastatic, PD-L1–positive HNSCC.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center appointed new members to advance the institute’s immunotherapy work.

Igor Makhlin, MD, notes the imaging modalities used in metastatic breast cancer and highlights FES-PET/CT as a specific modality for ER-positive disease.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

Read a refresh of the top FDA news in breast cancer from February 2026, including upcoming decision dates, a fast-tracked drug, and REMS safety updates.

Pirtobrutinib has been approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma in China.

Serial liquid biopsies consistently showed AR alterations linked to poorer outcomes, and findings support “real-time” molecular testing to guide personalized care.